99 related articles for article (PubMed ID: 24719935)
41. [Radical Chemoradiotherapy for Recurrent Esophageal Cancer after Curative Esophagectomy].
Nakajima T; Ogata T; Nomiya T; Nonaka T; Nakayama Y; Kano K; Maezawa Y; Segami K; Ikeda K; Sato T; Cho H; Yoshikawa T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1564-1566. PubMed ID: 28133058
[TBL] [Abstract][Full Text] [Related]
42. Reassessment of the role of enteral tube feedings for patients with esophageal cancer.
Starr B; Davis S; Ayala-Peacock D; Blackstock WA; Levine EA
Am Surg; 2014 Aug; 80(8):752-8. PubMed ID: 25105392
[TBL] [Abstract][Full Text] [Related]
43. Metachronous adenocarcinoma of the remnant oesophagus 15 years following multimodal therapy.
Croghan S; McCormack O; Muldoon C; Ravi N; Reynolds JV
Ir Med J; 2015 Jan; 108(1):22-3. PubMed ID: 25702351
[TBL] [Abstract][Full Text] [Related]
44. Chemoradiotherapy in esophageal cancer: toxicity is in the eye of the beholder.
Ilson DH
J Thorac Oncol; 2009 Mar; 4(3):277-8. PubMed ID: 19247080
[No Abstract] [Full Text] [Related]
45. [Potential influence of pre and intraoperative factors on postoperative recurrence and survival in patients undergoing radical resection of esophageal cancer].
Satomoto M; Suzuki A; Uchida T; Miyawaki Y; Kawano T; Makita K
Masui; 2014 Dec; 63(12):1344-9. PubMed ID: 25669088
[TBL] [Abstract][Full Text] [Related]
46. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer.
Kishida Y; Tsushima T; Endo M; Hamauchi S; Todaka A; Yokota T; Machida N; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
Am J Clin Oncol; 2018 Jan; 41(1):41-45. PubMed ID: 26422718
[TBL] [Abstract][Full Text] [Related]
47. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review.
Baxi SH; Burmeister B; Harvey JA; Smithers M; Thomas J
J Med Imaging Radiat Oncol; 2008 Dec; 52(6):583-7. PubMed ID: 19178634
[TBL] [Abstract][Full Text] [Related]
48. Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013.
Bernards N; Haj Mohammad N; Creemers GJ; Rozema T; Roukema JA; Nieuwenhuijzen GA; van Laarhoven HW; van der Sangen M; Lemmens VE
Acta Oncol; 2016; 55(9-10):1161-1167. PubMed ID: 27174793
[TBL] [Abstract][Full Text] [Related]
49. [Treatment Outcomes and Prognosis of Patients with Recurrent Diseases after Esophagectomy for Esophageal Cancer].
Takemura M; Takii M; Oshima T; Tanaka Y; Fujio N; Nakatani S
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1352-1354. PubMed ID: 29394631
[TBL] [Abstract][Full Text] [Related]
50. Long-Term Survival in an Esophageal Cancer Patient with Multiple Recurrences.
Shrestha R; Tripathi R; Goyal P; Agarwal C; Gupta M; Mehta A; Doval DC
J Gastrointest Cancer; 2020 Jun; 51(2):695-697. PubMed ID: 31989443
[No Abstract] [Full Text] [Related]
51. Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancer.
Jingu K; Umezawa R; Yamamoto T; Matsushita H; Ishikawa Y; Kozumi M; Kubozono M; Takahashi N; Kadoya N; Takeda K
Jpn J Clin Oncol; 2017 Mar; 47(3):200-205. PubMed ID: 28031356
[TBL] [Abstract][Full Text] [Related]
52. [Comparison of treatments in patients with inoperable stage IV advanced esophageal cancer].
Lee GJ; Park MI; Gwoo S; Jung HJ; Kim JH; Park SJ; Moon W; Kim HH; Kim YS; Park SD; Jeong TS
Korean J Gastroenterol; 2012 Apr; 59(4):282-8. PubMed ID: 22544025
[TBL] [Abstract][Full Text] [Related]
53. ASO Author Reflections: More May Not Be Better.
Worrell SG; Linden PA
Ann Surg Oncol; 2020 Feb; 27(2):509-510. PubMed ID: 31673943
[No Abstract] [Full Text] [Related]
54. The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.
Schizas D; Lazaridis II; Moris D; Mastoraki A; Lazaridis LD; Tsilimigras DI; Charalampakis N; Liakakos T
World J Surg Oncol; 2018 Mar; 16(1):55. PubMed ID: 29540179
[TBL] [Abstract][Full Text] [Related]
55. Chemical ablation therapy of recurrent mediastinal nodal metastasis in post-radiotherapy cancer patients.
Xu X; Li X; Ye X; Liu G; Wang J; Peng Z; Liang T; Yang W; Hao X
Med Oncol; 2014 Oct; 31(10):224. PubMed ID: 25204412
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors in esophageal cancer treated with curative intent.
Vendrely V; Launay V; Najah H; Smith D; Collet D; Gronnier C
Dig Liver Dis; 2018 Oct; 50(10):991-996. PubMed ID: 30166221
[TBL] [Abstract][Full Text] [Related]
57. [Therapeutic Strategies with Multidisciplinary Local Therapy for Postoperative Recurrence of Esophageal Cancer].
Okamoto K; Ninomiya I; Hirose A; Kinoshita J; Nakamura K; Oyama K; Miyashita T; Tajima H; Takamura H; Fushida S; Takanaka T; Ohta T
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1490-1492. PubMed ID: 28133033
[TBL] [Abstract][Full Text] [Related]
58. Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer.
Lutkenhaus LJ; Kamphuis M; van Wieringen N; Hulshof MC; Bel A
Radiother Oncol; 2013 Nov; 109(2):200-3. PubMed ID: 24094627
[TBL] [Abstract][Full Text] [Related]
59. Follow up of oesophageal cancer therapy at the Kenyatta National Hospital, Nairobi.
Ogendo SW
East Afr Med J; 2001 Dec; 78(12):650-4. PubMed ID: 12199447
[TBL] [Abstract][Full Text] [Related]
60. Influence of multimodality therapy on the cellular immunity of patients with esophageal cancer.
Mafune K; Tanaka Y
Ann Surg Oncol; 2000 Sep; 7(8):609-16. PubMed ID: 11005560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
